2. Academic Validation
  3. Establishment and Use of Patient-Derived Xenograft Models for Drug Testing in Head and Neck Squamous Cell Carcinoma

Establishment and Use of Patient-Derived Xenograft Models for Drug Testing in Head and Neck Squamous Cell Carcinoma

  • STAR Protoc. 2020 Jun 3;1(1):100024. doi: 10.1016/j.xpro.2020.100024.
Christina Karamboulas 1,  Jalna Meens 1,  Laurie Ailles 1 2
Affiliations

Affiliations

  • 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
  • 2 Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
PMID: 33111077 DOI: 10.1016/j.xpro.2020.100024
Abstract

This protocol provides the steps required for the establishment of patient-derived xenograft (PDX) tumors for head and neck squamous cell carcinomas (HNSCCs) and their utility in examining drug responses. PDXs recapitulate the heterogeneity observed in the corresponding human tumors, which makes them an ideal pre-clinical model system. This protocol outlines the detailed steps required for (1) the generation of HNSCC-PDXs, (2) the processing of tumor tissues, and (3) the expansion of PDX models into cohorts for (4) drug testing. For complete details on the use and execution of this protocol please refer to Karamboulas et al. (2018).

Figures
Products